TrialRheumatology (Oxford, England)2019

Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial.

Seung Cheol Shim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.